This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
SNAP-8 (10 mg Vial)
SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research.
Quick Reference
What is SNAP-8?
Concentration and Schedule
Developer active reference: Approximately 0.0015% to 0.005% active SNAP-8.
Best documented conventional cream example: Approximately 0.005% active peptide.
Application context: Twice daily around the eye area for 28 days in manufacturer testing.
Academic serum context: Morning and evening or twice-daily use for 12 weeks in multi-ingredient studies.
Patch context: Overnight nightly through day 14, then every third day through day 28 in a manufactured multi-active patch.
Storage Instructions
Follow the vial supplier’s lot-specific storage documentation before formulation.
Store the finished batch according to its validated base, preservative, pH, container, and stability plan.
Do not transfer the trade solution’s published shelf life to a raw-vial formulation.
An analytical standard remained stable for 96 hours at 4 degrees C, but that does not establish cosmetic-product shelf life[5].
How is SNAP-8 studied?
SNAP-8 is acetyl octapeptide-3, an eight-amino-acid peptide modeled on part of SNAP-25. Its sequence is Ac-EEMQRRAD-NH2[7]. The proposed cosmetic mechanism is interference with SNARE-complex assembly and calcium-dependent exocytosis. Direct SNAP-8 mechanism data are primarily developer-generated, so biological plausibility is not equivalent to proof of clinical muscle relaxation.
SNAP-8 is distinct from acetyl hexapeptide-8, also called Argireline. Argireline studies are related-peptide background, not direct SNAP-8 evidence.
What does the research report about SNAP-8?
Wrinkle measurements: Studies used silicone replicas, profilometry, three-dimensional imaging, or investigator grading.
Combination patch: Shin and colleagues reported improvements in selected wrinkle and skin-quality measures versus an HA-only patch, with no adverse effects reported during 28 days[1].
Multi-active patch: Avcil and colleagues reported product-level changes in fine lines, hydration, density, and thickness, with excellent tolerability[2].
Serum studies: Multi-ingredient studies reported selected appearance and hydration improvements, but the effect of SNAP-8 cannot be isolated[3][4].
Formulation safety: Tolerability of a commercial formula or manufactured patch does not establish preservation, uniformity, or safety of a new raw-vial formulation.
Route / Formulation-Specific Research
Human SNAP-8 Research Formulations
Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone.
Study | Formulation | Schedule | Design Context | Evidence Limit
Lipotec developer panel [6] | Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide | Twice daily around the eye area for 28 days | 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported | Manufacturer-reported, not an independent peer-reviewed trial
Shin et al. (2024) [1] | 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA | Overnight nightly through day 14, then every third day through day 28 | 24 enrolled and 21 completed a split-face active-versus-placebo comparison | Combination device; SNAP-8’s independent contribution cannot be isolated
Avcil et al. (2020) [2] | HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts | 12-week study | Fine lines, hydration, dermal density, thickness, and tolerability measures | Multi-active product; SNAP-8 concentration was not disclosed in the abstract
Draelos et al. (2016) [3] | Multi-peptide serum containing SNAP-8 within a supporting skincare regimen | Morning and evening for 12 weeks after a 2-week washout | 29 women; investigator grading and participant questionnaires | Open label, no control, multiple peptides and supporting products
Moy et al. (2023) [4] | Proprietary multi-peptide facial serum containing acetyl octapeptide-3 | Twice daily for 12 weeks | 31 women completed dermatologist grading, imaging, hydration, and questionnaires | Uncontrolled, multi-ingredient, and company funded
Research Limitations / Risk Notes
Published human SNAP-8 research uses complete topical products and localized dissolving patches. Interpret each result with its vehicle, co-ingredients, delivery system, application schedule, and measurement method.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
Research FAQs
1 What is the SNAP-8 dosage from a 10 mg vial?
For topical research, dosage is a finished concentration. A complete 10 mg vial produces 0.005% active SNAP-8 in a final 200 g batch. A 50 g batch at the same concentration uses 2.5 mg.
2 Does 10% SNAP-8 mean 10% pure peptide?
No. In developer materials, 10% refers to a nominal 0.05% supplier solution. The finished active concentration is about 0.005%, equal to 50 ppm[6].
3 What conventional cream concentration has the clearest context?
The best documented example used about 0.005% active SNAP-8 twice daily for 28 days in a small manufacturer panel. It is a formulation reference, not an independently replicated treatment standard.
4 Can a 0.03% microneedle patch be copied as a 0.03% cream?
No direct equivalence has been established. The patch combined SNAP-8 with other actives and used 350 micrometer dissolving microneedles[1].
5 What route has been evaluated in human research?
Human studies and developer testing evaluated topical creams, multi-peptide serums, and purpose-built dissolving microneedle patches. This review identified no peer-reviewed human or animal injection dosing study for acetyl octapeptide-3, so topical data are not converted into an injection schedule.